Peer-Reviewed Publication
Lancet Reg Health Am2026;58101457.June 1, 2026Journal Article
Remote digital intervention targeting heart failure medical therapy: a randomized controlled trial.
Adam D DeVore1,2, Cynthia L Green1,3, Nancy M Albert4, Amir R Haghighat5, Sunit-Preet Chaudhry6, Hirak Shah7, Mosi K Bennett8, Tom Stanis9, Ashul Govil9, Trejeeve Martyn10, Jaime McDermott2, Mirza S Khan11, Andrew J Sauer11
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
2Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
3Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
4Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, USA.
5Cardiovascular Institute of Northwest Florida, Panama City, FL, USA.
6Ascension St. Vincent, Indianapolis, IN, USA.
7University of Kansas Medical Center, Kansas City, KS, USA.
8Allina Health Minneapolis Heart Institute, Minneapolis, MN, USA.
9Story Health, Cupertino, CA, USA.
10Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
11Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
Abstract
BACKGROUND: Heart failure (HF) causes substantial morbidity and mortality, in part because evidence-based pharmacotherapies remain underused. Remote, asynchronous digital platforms may accelerate the initiation and titration of pharmacotherapies outside of traditional clinic visits; however, their efficacy and safety have not been adequately tested in randomized trials.
METHODS: VITAL-HF (Virtual…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans